Fibofen-145 Tablet

Fenofibrate 145 mg — Lipid-Lowering Tablet

📱 WhatsApp Enquiry📞 Call: +919041677932

About Fibofen-145 Tablet

Fibofen-145 Tablet contains Fenofibrate 145 mg in a nanocrystalline formulation that provides good bioavailability with or without food. Fenofibrate is a peroxisome-proliferator-activated-receptor (PPAR)-alpha agonist with potent triglyceride-lowering and modest HDL-raising effects.

It is indicated for severe hypertriglyceridaemia, mixed dyslipidaemia, low-HDL states, diabetic dyslipidaemia and as adjunct to statins in patients with persistent triglyceride elevation.

Camrut Healthcare manufactures Fibofen-145 under WHO-GMP conditions for PCD pharma franchise across India.

Indications

• Severe hypertriglyceridaemia (TG > 500 mg/dL)
• Mixed dyslipidaemia
• Low HDL cholesterol with high triglycerides
• Diabetic dyslipidaemia
• Adjunct to statins in residual hypertriglyceridaemia

Mechanism of Action

Fenofibrate activates PPAR-alpha, a nuclear transcription factor regulating lipid metabolism genes. This increases lipoprotein lipase activity (clearing triglyceride-rich particles), decreases apoC-III (an LPL inhibitor) and increases apoA-I synthesis (raising HDL). Net effects: 30–50% reduction in triglycerides and modest 5–20% increase in HDL.

Dosage & Administration

['Adults: 1 tablet (145 mg) once daily, with or without food', 'Take with adequate water', 'Monitor lipids every 3 months', 'Periodic monitoring of liver function and CK']

Side Effects

['Mild GI upset', 'Myalgia and muscle weakness', 'Elevated liver enzymes', 'Increased serum creatinine', 'Cholelithiasis with prolonged use']

Contraindications & Precautions

['Severe hepatic impairment', 'Severe renal impairment (eGFR < 30)', 'Pre-existing gallbladder disease', 'Hypersensitivity to fenofibrate', 'Pregnancy and breastfeeding']

Storage

Store below 25°C.

Frequently Asked Questions

Related Products